UCB Licenses BioWa Antibody Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgian company aims to develop ADCC therapies for oncology, inflammatory disease targets.
You may also be interested in...
UCB Receives “Complete Response” Letter For Cimzia
Firm says FDA seeks new information and clarification regarding the BLA.
MedImmune Expands BioWa Licensing Deal To Boost Anti-Inflammatory Pipeline
Collaboration includes Phase I monoclonal antibody targeting interleukin-5 and BioWa’s antibody-enhancing technology.
FDA Lifts Clinical Hold On UCB/Immunomedics Epratuzumab Lupus Trial
Firms will submit protocol amendments to institutional review boards.